| Dr Jan Ferris, DO | |
|
28 Park Ave, Williston, VT 05495-9701 | |
| (802) 878-1008 | |
| (802) 872-2679 |
| Full Name | Dr Jan Ferris |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 36 Years |
| Location | 28 Park Ave, Williston, Vermont |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588774608 | NPI | - | NPPES |
| 0VN1022 | Medicaid | VT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 0320000431 (Vermont) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Univ. Of Vermont - Fletcher Allen Health Care | Burlington, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Evergreen Family Health Partners | 1153402888 | 17 |
News Archive
The drug pentoxifylline appears to have limited benefit in the first-line treatment of mouth ulcers due to recurrent apthous stomatitis, according to a report in the April issue of Archives of Dermatology.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
The panel on July 22 will consider a measure repealing the current Medicare physician payment formula. Also in the news, some fact-checking on House GOP efforts to repeal the health law.
A pricy drug used to treat a rare but well-known genetic disorder may hold wider promise as a treatment for millions of Americans with potentially lethal enlarged hearts, due mainly to high blood pressure, a study from Johns Hopkins shows.
By establishing protein design algorithms that simultaneously optimize drug candidates for both decreased immunogenic epitope content and high level stability and activity, Dartmouth's Norris Cotton Cancer Center investigator Karl Griswold, PhD, and his collaborator Chris Bailey-Kellogg, PhD, have established a novel testing platform.
› Verified 3 days ago
| Entity Name | Evergreen Family Health Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588790562 PECOS PAC ID: 1153402888 Enrollment ID: O20080118000342 |
News Archive
The drug pentoxifylline appears to have limited benefit in the first-line treatment of mouth ulcers due to recurrent apthous stomatitis, according to a report in the April issue of Archives of Dermatology.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
The panel on July 22 will consider a measure repealing the current Medicare physician payment formula. Also in the news, some fact-checking on House GOP efforts to repeal the health law.
A pricy drug used to treat a rare but well-known genetic disorder may hold wider promise as a treatment for millions of Americans with potentially lethal enlarged hearts, due mainly to high blood pressure, a study from Johns Hopkins shows.
By establishing protein design algorithms that simultaneously optimize drug candidates for both decreased immunogenic epitope content and high level stability and activity, Dartmouth's Norris Cotton Cancer Center investigator Karl Griswold, PhD, and his collaborator Chris Bailey-Kellogg, PhD, have established a novel testing platform.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jan Ferris, DO 28 Park Ave, Williston, VT 05495-9701 Ph: (802) 878-1008 | Dr Jan Ferris, DO 28 Park Ave, Williston, VT 05495-9701 Ph: (802) 878-1008 |
News Archive
The drug pentoxifylline appears to have limited benefit in the first-line treatment of mouth ulcers due to recurrent apthous stomatitis, according to a report in the April issue of Archives of Dermatology.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
The panel on July 22 will consider a measure repealing the current Medicare physician payment formula. Also in the news, some fact-checking on House GOP efforts to repeal the health law.
A pricy drug used to treat a rare but well-known genetic disorder may hold wider promise as a treatment for millions of Americans with potentially lethal enlarged hearts, due mainly to high blood pressure, a study from Johns Hopkins shows.
By establishing protein design algorithms that simultaneously optimize drug candidates for both decreased immunogenic epitope content and high level stability and activity, Dartmouth's Norris Cotton Cancer Center investigator Karl Griswold, PhD, and his collaborator Chris Bailey-Kellogg, PhD, have established a novel testing platform.
› Verified 3 days ago
Mr. Scott A Paluska, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 28 Park Ave, Williston, VT 05495 Phone: 802-878-1008 Fax: 802-872-2679 | |
Miss Nancy Irene Resi, FNP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 28 Park Ave, Williston, VT 05495 Phone: 802-878-1008 | |
Dr. Rebecca Lynne Joyce, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 28 Park Ave, Williston, VT 05495 Phone: 802-878-1008 Fax: 802-872-2679 | |
Adriane Cross Trout, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 586 Oak Hill Rd, Williston, VT 05495 Phone: 802-878-8131 Fax: 802-879-6853 | |
Pamela Jane Dawson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 586 Oak Hill Rd, Williston, VT 05495 Phone: 802-878-8131 Fax: 802-879-6853 | |
Dr. David Nicholas Simcoe, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 586 Oak Hill Rd, Williston, VT 05495 Phone: 802-878-8131 Fax: 802-879-6853 | |
Stephen E Mann, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 586 Oak Hill, Williston, VT 05495 Phone: 802-878-8131 |